Multiple Sclerosis Journal · 2016 · 288 citations · 23 references
Life SciencesNeurologyNeuroscienceClinical NeuroscienceNeurodegenerationNeurologic PharmacotherapyMultiple SclerosisMultiple Sclerosis PharmacotherapyNeurodegenerative DiseasesNeuroinflammationNeurological AssessmentDisease Activity MeasurementFingolimod TherapyInflammatory Activity ImagingMultiple Sclerosis TherapyPlacebo-controlled Efficacy AssessmentRelapsing-remitting Multiple Sclerosis TreatmentTreatment Response BiomarkersTreatment Response Criteria
BACKGROUND: 'No evidence of disease activity' (NEDA), defined as absence of magnetic resonance imaging activity (T2 and/or gadolinium-enhanced T1 lesions), relapses and disability progression ('NEDA-3'), is used as a comprehensive measure of treatment response in relapsing multiple sclerosis (RMS), but is weighted towards inflammatory activity. Accelerated brain volume loss (BVL) occurs in RMS and is an objective measure of disease worsening and progression. OBJECTIVE: To assess the contribution of individual components of NEDA-3 and the impact of adding BVL to NEDA-3 ('NEDA-4') METHODS: We analysed data pooled from two placebo-controlled phase 3 fingolimod trials in RMS and assessed NEDA-4 using different annual BVL mean rate thresholds (0.2%-1.2%). RESULTS: At 2 years, 31.0% (217/700) of patients receiving fingolimod 0.5 mg achieved NEDA-3 versus 9.9% (71/715) on placebo (odds ratio (OR) 4.07; p < 0.0001). Adding BVL (threshold of 0.4%), the respective proportions of patients achieving NEDA-4 were 19.7% (139/706) and 5.3% (38/721; OR 4.41; p < 0.0001). NEDA-4 status favoured fingolimod across all BVL thresholds tested (OR 4.01-4.41; p < 0.0001). CONCLUSION: NEDA-4 has the potential to capture the impact of therapies on both inflammation and neurodegeneration, and deserves further evaluation across different compounds and in long-term studies.
23
Cortical demyelination and diffuse white matter injury in multiple sclerosis
Alexandra Kutzelnigg, Claudia F. Lucchinetti, Christine Stadelmann et al. · Brain · 2005 · 1.8K citations
The relation between inflammation and neurodegeneration in multiple sclerosis brains
Josa M. Frischer, Stephan Bramow, Assunta Dal‐Bianco et al. · Brain · 2009 · 1.4K citations · Full text
Peter A. Calabresi, Ernst-Wilhelm Radüe, Douglas S. Goodin et al. · The Lancet Neurology · 2014 · 822 citations